JP2010523559A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523559A5
JP2010523559A5 JP2010502079A JP2010502079A JP2010523559A5 JP 2010523559 A5 JP2010523559 A5 JP 2010523559A5 JP 2010502079 A JP2010502079 A JP 2010502079A JP 2010502079 A JP2010502079 A JP 2010502079A JP 2010523559 A5 JP2010523559 A5 JP 2010523559A5
Authority
JP
Japan
Prior art keywords
phenoxy
polymorph
diethylamine
chloro
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010502079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003325 external-priority patent/WO2008123914A1/en
Publication of JP2010523559A publication Critical patent/JP2010523559A/ja
Publication of JP2010523559A5 publication Critical patent/JP2010523559A5/ja
Pending legal-status Critical Current

Links

JP2010502079A 2007-04-05 2008-03-12 ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 Pending JP2010523559A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92196407P 2007-04-05 2007-04-05
US92578607P 2007-04-23 2007-04-23
PCT/US2008/003325 WO2008123914A1 (en) 2007-04-05 2008-03-12 Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Publications (2)

Publication Number Publication Date
JP2010523559A JP2010523559A (ja) 2010-07-15
JP2010523559A5 true JP2010523559A5 (enExample) 2011-03-31

Family

ID=39469930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010502079A Pending JP2010523559A (ja) 2007-04-05 2008-03-12 ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態

Country Status (11)

Country Link
US (2) US7884219B2 (enExample)
EP (1) EP2144883A1 (enExample)
JP (1) JP2010523559A (enExample)
AR (1) AR065896A1 (enExample)
CA (1) CA2681864A1 (enExample)
CL (1) CL2008000987A1 (enExample)
PA (1) PA8775601A1 (enExample)
PE (1) PE20090808A1 (enExample)
TW (1) TW200900384A (enExample)
UY (1) UY31004A1 (enExample)
WO (1) WO2008123914A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2144883A1 (en) * 2007-04-05 2010-01-20 TransTech Pharma, Inc Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
MX377733B (es) * 2012-10-05 2025-03-11 Vtv Therapeutics Llc Tratamiento de enfermedad de alzheimer leve y moderada.
CN103726005A (zh) * 2012-10-16 2014-04-16 深圳富泰宏精密工业有限公司 珐琅涂层的制造方法及其制品
WO2019190822A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
CA3110582A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
WO2020086388A1 (en) 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529110T1 (de) * 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
EP2144883A1 (en) * 2007-04-05 2010-01-20 TransTech Pharma, Inc Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Similar Documents

Publication Publication Date Title
JP2010523559A5 (enExample)
US10633368B2 (en) Voriconazole intermediate and voriconazole synthesis method
Sun et al. A green luminescent 1-D helical tubular dipyrazol-bridged cadmium (II) complex: a coordination tube included in a supramolecular tube
Sangeetha et al. Vibrational, DFT, and thermal analysis of 2, 4, 6-triamino-1, 3, 5-triazin-1-ium 3-(prop-2-enoyloxy) propanoate acrylic acid monosolvate monohydrate
CN104447804B (zh) 间苯双三唑Cu-三氟甲磺酸配合物及其制备方法与应用
CN103242193B (zh) 一种羟肟化杯[6]芳烃高效铀萃取剂的制备及其用途
WO2007047838A2 (en) Process for preparing olmesartan medoxomil
EP2809665A1 (en) Process for the preparation of vilazodone or its pharmaceutically acceptable salts
CN104370900B (zh) 一种盐酸阿罗洛尔的制备方法
CN105777617B (zh) 色瑞替尼的合成中间体及其制备方法
JP2012524736A5 (enExample)
Morshedi et al. Mixed halide/oxoanion-templated frameworks
WO2017131218A1 (ja) アジルサルタン及びその製造方法
CN119255852A (zh) 吡啶酰胺杀真菌剂化合物的结晶形式
JP7177796B2 (ja) アジルサルタンａ型結晶の製造方法
Shen et al. A novel fluorescent dye naphthalene imide-Fluorine boron two pyrrole: synthesis, fluorescence resonance energy transfer and cell imaging
CN102050796B (zh) α,α,α',α'-四甲基-5-(1氢-1,3,4-三氮唑-1-基甲基)-1,3-苯二乙腈的制备方法
JP4921497B2 (ja) 多環式３級アミンの製造方法
JP5575783B2 (ja) トリフェニルメタン保護基の除去方法
CN103319472B (zh) 一种伊潘立酮的制备方法
CN106749202A (zh) 一种立福康唑中间体的制备方法
JP6663232B2 (ja) 新規結晶構造を有するアジルサルタン及びその製造方法
EP2542550A1 (en) Process for the direct preparation of malic acid salt of sunitinib
CN101993419B (zh) 一种4-［（5-溴-4，6-二氯-2-嘧啶基）氨基］苯甲腈的制备方法
CN102050775A (zh) 阿那曲唑杂质α,α,α′,α′-四甲基-5-(丁二酰亚胺-1-基甲基)-1,3-苯二乙腈及其制备方法